Quick Answer
Spyre Therapeutics, Inc. reported Diluted EPS of $49.12 per share (loss) for fiscal year 2023.
Spyre Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$49.12 | -97.6% |
| 2022 | -$24.86 | +0.6% |
| 2021 | -$25.02 | -1546.1% |
| 2020 | -$1.52 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$1.36 | +85.4% | -58.1% |
| June 30, 2024 | -$0.86 | +98.5% | +28.3% |
| March 31, 2024 | -$1.20 | +75.5% | +87.2% |
| September 30, 2023 | -$9.34 | -93.0% | +83.6% |
| June 30, 2023 | -$56.79 | -20933.3% | -1061.3% |
| March 31, 2023 | -$4.89 | -1221.6% | -1.0% |
| September 30, 2022 | -$4.84 | -1461.3% | -1692.6% |
| June 30, 2022 | -$0.27 | -170.0% | +27.0% |
- Spyre Therapeutics, Inc. showed a decrease of -97.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2023 period, Spyre Therapeutics, Inc.’s diluted eps has declined by 3131.6% (from $1.52 per share (loss) to $49.12 per share (loss)).
- The most recent figure is from Spyre Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 29, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: